Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

Rhea-AI Summary

Keros Therapeutics (Nasdaq: KROS) entered an agreement on March 9, 2026, with Massachusetts General Hospital to design a Phase 2 clinical trial evaluating rinvatercept in ALS patients under the Healey ALS MyMatch program.

The collaboration will use biomarker-driven, personalized trial methods to match ALS subgroups to experimental therapies and to identify optimal populations for later-stage trials.

Positive

• Selected to Healey ALS MyMatch program for ALS trial collaboration
• Agreement to design a Phase 2 clinical trial for rinvatercept
• Trial will use biomarker-driven personalized matching of ALS subgroups

Negative

• Clinical program remains early-stage (Phase 1b/2a series), efficacy unproven
• Press release provides no new quantitative clinical outcomes or timelines

Key Figures

Phase 2 trial: Phase 2 ALS MyMatch stages: Phase 1b/2a

2 metrics

Phase 2 trial Phase 2 Planned ALS MyMatch clinical trial of rinvatercept

ALS MyMatch stages Phase 1b/2a Early-stage trials within ALS MyMatch program

Market Reality Check

Price: $11.35 Vol: Volume 637,632 is 1.78x t...

high vol

$11.35 Last Close

Volume Volume 637,632 is 1.78x the 20-day average of 358,674, indicating elevated trading activity pre-announcement. high

Technical Shares at $11.30 are trading below the 200-day moving average of $16.07 and well under the $22.55 52-week high.

Peers on Argus

KROS fell 3.5% while peers were mixed: ANAB down 0.17%, PVLA up 2.19%, BCAX up 1...

KROS fell 3.5% while peers were mixed: ANAB down 0.17%, PVLA up 2.19%, BCAX up 1.21%, RIGL up 0.21%, TYRA up 1.62%, indicating a stock-specific move rather than a broad biotech reaction.

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Earnings and pipeline	Positive	-15.0%	Reported 2025 net income and outlined Phase 2 plans for rinvatercept.
Feb 26	Board change	Neutral	-5.6%	Appointed Charles Newton to Board while another director resigned.
Feb 18	Conference participation	Neutral	+2.4%	Announced CEO presentations at multiple upcoming healthcare conferences.
Nov 20	Tender offer final	Positive	+3.4%	Final results of cash tender repurchasing shares under capital return program.
Nov 19	Tender offer prelim	Positive	-3.9%	Preliminary results of substantial share repurchase tender offer.

Pattern Detected

Recent history shows several positive or strategic updates followed by negative price reactions, suggesting a tendency for the stock to sell off on good news.

Recent Company History

Over the past few months, Keros has reported a move to $87.0M net income in 2025, advanced plans for Phase 2 trials of rinvatercept in DMD and ALS, and completed a large tender offer repurchasing up to 10,950,165 shares under a $375M capital return program. Board changes and conference participation rounded out the cadence of updates. Despite these developments, several announcements with seemingly constructive fundamentals coincided with negative share reactions, framing today’s ALS collaboration within a pattern of cautious market response.

Market Pulse Summary

This announcement adds an ALS-focused collaboration with the Healey ALS MyMatch program, moving rinv...

Analysis

This announcement adds an ALS-focused collaboration with the Healey ALS MyMatch program, moving rinvatercept toward a biomarker-driven Phase 2 trial in amyotrophic lateral sclerosis. It builds on prior disclosures that the company plans multiple Phase 2 programs for rinvatercept across neuromuscular indications. Investors may track trial initiation, design details, and any early Phase 1b/2a-style data readouts, alongside existing financial strength highlighted in recent filings, to gauge how this partnership shapes the broader development trajectory.

Key Terms

transforming growth factor-beta, tgf-ß, amyotrophic lateral sclerosis, als, +3 more

7 terms

transforming growth factor-beta medical

"disorders that are linked to dysfunctional signaling of the transforming growth factor-beta"

Transforming growth factor-beta (TGF-β) is a naturally occurring signaling protein that helps control cell growth, inflammation and tissue repair, acting like a traffic cop that tells cells when to divide, change form or calm down. It matters to investors because drugs that block or boost TGF-β can treat cancers, fibrotic diseases and immune disorders, affecting clinical trial outcomes, regulatory risk and the commercial potential of biopharma assets.

tgf-ß medical

"dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins"

Transforming growth factor beta (TGF-ß) is a naturally occurring protein that helps cells talk to each other and controls processes like growth, scarring and immune response. Think of it as a traffic signal for tissues that can either slow down or redirect cell behavior. Investors watch TGF-ß because drugs that change its signals can treat cancer, fibrosis and immune diseases, so changes in research results or regulatory news can strongly affect a biotech’s value.

amyotrophic lateral sclerosis medical

"evaluating rinvatercept in patients with amyotrophic lateral sclerosis (“ALS”)"

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

als medical

"patients with amyotrophic lateral sclerosis (“ALS”) within the Healey ALS MyMatch program"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages the nerve cells controlling muscles, gradually causing weakness, loss of movement and difficulty breathing — similar to the body’s wiring slowly failing. For investors, ALS matters because research progress, clinical trial results, regulatory approvals or setbacks can dramatically affect the value of companies developing treatments, patient-care markets and related healthcare services.

biomarker medical

"accelerating the development of new therapies for ALS by harnessing the power of biomarker-driven"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

phase 2 medical

"design of a Phase 2 clinical trial evaluating rinvatercept in patients"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 1b/2a medical

"ongoing series of early-stage Phase 1b/2a clinical trials aimed at deepening"

Phase 1b/2a is a combined early-stage clinical study that first tests safety and optimal dosing in a small group and then expands to look for initial signs that the drug works in the target patients. Think of it as a prototype test followed by a small pilot run: it helps companies decide whether to invest in larger, more expensive trials. Investors watch these results because they reduce scientific uncertainty and can sharply affect a drug’s value and development timeline.

AI-generated analysis. Not financial advice.

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital (“MGH”) for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis (“ALS”) within the Healey ALS MyMatch program (“ALS MyMatch”), led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham.

The collaboration is in response to the Healey & AMG Center’s call for applications for the ALS MyMatch program. The ALS MyMatch program is accelerating the development of new therapies for ALS by harnessing the power of biomarker-driven personalized trial approaches. By integrating comprehensive genetic and biofluid markers, the program matches subgroups of ALS individuals to various experimental therapies based on their disease markers. ALS MyMatch is an ongoing series of early-stage Phase 1b/2a clinical trials aimed at deepening the understanding of biological effects of experimental products and identifying the optimal population for future later-stage Phase 2/3 clinical trials.

“We are proud to be selected to the ALS MyMatch program to collaborate with the Healey & AMG Center at Mass General,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “Rinvatercept represents a potentially novel approach to treat patients with ALS. Based on the data we have generated to date, we believe there is a strong scientific rationale for the potential of rinvatercept to preserve muscle strength and function and improve quality of life in patients with ALS.”

“ALS is a serious, progressive disorder with need of additional treatment options,” said Merit Cudkowicz, M.D., M.Sc., director of the Sean M. Healey & AMG Center for ALS, executive director of the Neuroscience Institute at Mass General Brigham, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. “We look forward to partnering with Keros to evaluate rinvatercept within the ALS MyMatch program, bringing us closer to our goal of finding additional treatments for those battling ALS.”

About Healey ALS MyMatch

Healey ALS MyMatch is a multi-site, collaborative initiative that currently brings together four trial-ready, high enrolling ALS research centers and is a Network of Excellence for ALS (NEALS) affiliated program. Research centers include Mass General in Boston; University of Minnesota in Minneapolis, Minn.; Northwestern University in Evanston, Ill.; and Nova Southeastern University in Fort Lauderdale, Fla. ALS MyMatch has partnered with the Acceleration Centers of Enrollment (ACE) program, a community-driven philanthropic partnership program focused on expediting start up and recruitment at study centers. Additional trials and high performing sites will be added as the program grows.

About the Sean M. Healey & AMG Center for ALS at Mass General Brigham
The Sean M. Healey & AMG Center for ALS at Mass General Brigham, launched in 2018, brings together a global network of scientists, physicians, nurses, foundations, federal agencies and people living with ALS, their loved ones, and caregivers to accelerate the pace of ALS therapy discovery and development.

About Rinvatercept

Rinvatercept is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB that is fused to the portion of the human antibody known as the Fc domain. Rinvatercept is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A, which are negative regulators of muscle and bone mass and strength, to improve skeletal muscle regeneration, increase muscle size and strength, inhibit and reduce fibrosis, inhibit inflammation, reduce fat accumulation and improve bone health through bone anabolic mechanisms. We are developing rinvatercept for the treatment of Duchenne muscular dystrophy and for the treatment of ALS.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of ALS. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “believe,” “forward,” “goal,” “potential” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: the potential of rinvatercept to preserve muscle strength and function and improve quality of life in patients with ALS. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K, filed with the SEC on March 4, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts

Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042

Media Contact:
Mahmoud Siddig / Adam Pollack / Viveca Tress
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

FAQ

What did Keros (KROS) announce on March 9, 2026 about rinvatercept and ALS?

Keros announced an agreement with Massachusetts General Hospital to design a Phase 2 trial of rinvatercept in ALS patients. According to Keros, the work will occur within the Healey ALS MyMatch program using biomarker-driven personalized trial methods.

How will the Healey ALS MyMatch program evaluate rinvatercept in the KROS collaboration?

The program will match ALS subgroups to experimental therapies using genetic and biofluid biomarkers. According to Keros, this approach aims to identify the optimal population for future Phase 2/3 trials and deepen biological understanding.

Does the March 9, 2026 announcement say rinvatercept is effective for ALS?

No — the announcement describes a trial design collaboration, not efficacy results. According to Keros, current data provide scientific rationale but no new clinical outcomes were reported in this release.

What stage of development is rinvatercept after the KROS–MGH agreement?

Rinvatercept is advancing to a Phase 2 trial design under the Healey ALS MyMatch program. According to Keros, the program follows an early-stage Phase 1b/2a series focused on biomarker-driven evaluation.

How might the Keros collaboration affect KROS shareholders and clinical progress?

The collaboration could accelerate patient-matched trial enrollment and clarify target populations for later trials. According to Keros, the partnership aims to refine biological signals and inform future Phase 2/3 development plans.